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Enhancement of electroporation facilitated immunogene therapy
via T-reg depletion
PF Forde1, M Sadadcharam1, LJ Hall2, TR O’ Donovan1, M de Kruijf1, WL Byrne1, GC O’ Sullivan1 and DM Soden1
Regulatory T cells (T-regs) can negatively impact tumor antigen-speciﬁc immune responses after inﬁltration into tumor tissue.
However, depletion of T-regs can facilitate enhanced anti-tumor responses, thus augmenting the potential for immunotherapies.
Here we focus on treating a highly aggressive form of cancer using a murine melanoma model with a poor prognosis. We utilize
a combination of T-reg depletion and immunotherapy plasmid DNA delivered into the B16F10 melanoma tumor model via
electroporation. Plasmids encoding murine granulocyte macrophage colony-stimulating factor and human B71 were transfected
with electroporation into the tumor and transient elimination of T-regs was achieved with CD25-depleting antibodies (PC61). The
combinational treatment effectively depleted T-regs compared to the untreated tumor and signiﬁcantly reduced lung metastases.
The combination treatment was not effective in increasing the survival, but only effective in suppression of metastases. These
results indicate the potential for combining T-reg depletion with immunotherapy-based gene electrotransfer to decrease systemic
metastasis and potentially enhance survival.
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INTRODUCTION
The incidence of one of the most intractable forms of skin cancer,
malignant melanoma, continues to rise, while at the same time
current treatment regimes show limited impact on survival.1
Existing treatment strategies include surgery, chemotherapy and
radiotherapy, however many patients succumb to local regional
and distal reoccurrences.2–4 Current management of melanoma
relies on primary prevention and early detection of disease2,5 and
new treatment approaches that are more tolerable, reduce the risk
of relapse and do not impinge on the patient’s quality of life are
urgently required.
Conventional therapies have demonstrated poor anti-cancer effects
for reasons such as chemoresistance and rapid metastasis.6–9
Due to its inherent poor prognosis compounded by ineffec-
tive treatment regimens, there is a signiﬁcant drive to design
diverse treatment strategies against melanoma, with immuno-
therapy representing a key therapy focus.10 The goal of immuno-
therapy is to increase overall anti-tumor immunity and thus
represents a potent means for cancer treatment. However, a major
obstacle to the success of immunotherapy is the presence of
negative factors that inhibit the immune system such as regula-
tory T cells (T-regs).11 T-regs have been implicated as one of the
major suppressive mechanisms of anti-tumor immune responses.
Increased levels of T-regs in tumors are often associated with
poor clinical outcome and tumor progression in various tumor
entities.11 In healthy immune homeostasis, T-regs (a subset of
T cells) play a crucial role in maintaining immunological
unresponsiveness to self-antigens and in suppressing excessive
immune responses that would otherwise be harmful to the host.12
However, in the tumor environment, T-reg-induced immune
suppression poses a signiﬁcant barrier to anti-cancer responses
targeted by immune-therapeutic strategies.12–14 We, and other
groups, have demonstrated that an increase or decrease in
T-regs has a direct inﬂuence on the effect of an immunotherapy
approach.15 Other studies have used different therapeutic appro-
aches including interleukin-12 and interleukin-2, which have
had signiﬁcant therapeutic responses.16–18 We have previously
reported that an immunotherapy DNA plasmid encoding the
cytokine granulocyte macrophage colony-stimulating factor (GM-
CSF; pGmCSF-b7.1), combined with pre-conditioned T-reg deple-
tion, was effective in the treatment of murine ﬁbrosarcoma.19
To determine the efﬁcacy of immunotherapy in aggressive
malignant melanoma we electrically delivered a plasmid encoding
GM-CSF, in combination with T-reg depleting anti-CD25 to mice
receiving the melanoma tumor cell line B16F10. Our results
demonstrate that this combinational approach signiﬁcantly reduced
tumor volume and systemic lung metastases and signiﬁcantly
improved overall survival time, and thus represents a promising
therapeutic approach against melanoma.
MATERIALS AND METHODS
Animals and tumor induction
Female C57BL/6 (6–8 weeks) mice were obtained from Harlan Laboratories
(Oxfordshire, UK). All in vivo experiments were approved by the ethics
committee of University College Cork and carried out under licenses issued
by the Department of Health, Ireland, as directed by the Cruelty to Animals
Act Ireland and EU Statutory Instructions. Mice were kept at a constant
room temperature (22 1C) with a natural day/night light cycle in a con-
ventional animal colony. Standard laboratory food and water were
provided ad libitum. The B16F10 cell line was obtained from the American
Type Culture Collection and cultured (Manassas, VA, USA) in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10%, v/v, fetal calf serum,
300mgml 1 L-glutamine. Tumor cells from a mid-log phase culture were
collected by brief exposure to 0.05% trypsing/EDTA solution, washed twice
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with phosphate-buffered saline. For routine tumor induction, 5 105
tumor cells suspended in 200ml of serum-free Dulbecco’s modiﬁed Eagle’s
medium were injected subcutaneously into the ﬂank of mice. Following
tumor establishment, tumors were allowed to grow and develop and were
monitored by alternate day measurements in two dimensions using
vernier calipers. Tumor volume was calculated according to the formula
V¼ ab2/6, where a is the longest diameter of the tumor and b is the
longest diameter perpendicular to diameter a. From these volumes, tumor
growth curves were constructed. Mice were culled when the tumor
diameter was approximately 1.5 cm.
Plasmids
The mammalian expression vector pMG was purchased from Invivogen
(Cayla SAS, Toulouise, France). A version of this plasmid, designated
pGT141, containing the murine GM-CSF and human B71 genes transcrip-
tionally controlled from the hEF1–HTLV and CMV promoters, respectively,
was designed and cloning was performed on contract by Invivogen.
Human B71 cDNA has been shown previously to function in a murine
setting. The inserts were conﬁrmed by sequencing. Plasmids were
propagated in Escherichia coli strain Top10 and puriﬁed on endotoxin-
free Qiagen-tip 500 columns (Qiagen, Manchester, UK).
In vivo T-reg cell depletion
The anti-CD25 monoclonal antibody (mAb; clone PC61) was used to
deplete and deactivate T-regs in mice. Mice were treated with anti-CD25
mAb by intraperitoneal injection in 0.25ml endonucleas-free phosphate-
buffered saline 1 day prior to performing experiments and every 4 days
post tumor induction. Rat IgG1 (HRPN, anti-peroxidase horseradish) was
used as a control (Bio-Express, West Lebanon, NH, USA). In previous studies
the minimum dose required for each mAb was 1mgkg 1 delivered
intraperitonealy to achieve 495% reduction in systemic T-reg numbers
without nonspeciﬁc T-cell activation.15 Validation that the control Ab had
no effect on T-reg numbers was achieved using ﬂuorescence-activated cell
sorter.
Flow cytometry analysis
Fluorescence-activated cell sorter analysis was performed using anti-
mouse PE-foxp3, FITC-CD4 and APC-CD25 and relevant isotype controls as
per manufacturer (eBiosciences, Insight Biotechologies, London, UK).
Single-cell suspensions from the spleens and tumors of individual mice
were prepared to obtain a ﬁnal concentration of 5 105 cells per well
in blocking buffer (1 phosphate-buffered saline/1% bovine serum
albumin/0.05% sodium azide/1% rat, hamster and mouse serum). A
quantity of 50ml of each mAb dye and 5 ml of the amine-reactive viability
dye ViViD (Invitrogen) to determine dead cells was added to the blocking
buffer. This was then incubated in the dark at 4 1C for 30min. Cells were
washed twice with blocking buffer and ﬁnally resuspended in 200ml 1%
paraformaldehyde. To perform ﬂow cytometric analyses and measure
relative ﬂuorescence intensities a FACS-Aria cytometer and BD Diva
software (BD Biosciences) were used. For each mouse, 20 000–200 000
events were recorded. The percentage of cells labeled with each mAb was
calculated in comparison with cells stained with isotype control Ab.
Background staining was controlled by labeled isotype controls (eBios-
ciences) and ﬂuorescence-minus-one controls. The results represent the
percentage of positively stained cells in the total cell population exceeding
the background staining signal. For determination of intracellular foxp3
production, cells were then ﬁxed and saponin permeabilized (Perm/ﬁx
solution, eBiosciences) and incubated with mAb or isotypic control mAb.
After 30min, cells were twice washed in permeabilization buffer
(eBiosciences) and then analyzed by ﬂow cytometry as described above.
In vivo electrogenetherapy
When tumors reached approximately 100mm3 in volume (5–7mm major
diameter), mice were randomly divided into experimental groups and
subjected to speciﬁc experimental protocols. The procedure was carried
out under general anesthesia, by intraperitoneal administration of 200mg
xylazine and 2mg ketamine. The skin overlying the ﬂank tumor was
shaved. Fifty mg of plasmid DNA in 50 ml sterile injectable phosphate-
buffered saline was injected into the tumor. Two-needle array electrodes
(Cork Cancer Research Centre, Cork, Ireland) were inserted on either side of
the marked DNA injection point 80 s after DNA delivery for electroporation.
The distance between the electrodes was 4mm. In vivo electropora-
tion parameters were 1200 V cm 1 100ms pulse length; 1 pulse and
120 V cm 1 20ms; 8 pulses at 1 Hz, and were administered in sequence
using the E.Pore Gx (Cork Cancer Research Centre, Cork, Ireland) square
wave generator. The high-voltage pulse was used to induce electropora-
tion in the cell membrane and the ensuing small voltage pulses were used
to create an electrophoretic ﬁeld to assist movement of the negative
charged DNA plasmid across the cells.
Statistical analysis
Experimental results were plotted and analyzed for signiﬁcance with Prism
4 software (GraphPad software, La Jolla, CA, USA). Po0.05 was considered
signiﬁcant.
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Figure 1. Tumor growth for anti-CD25 monoclonal antibody (mAb) treatments. (a) Experimental protocol. C57/BJ6 mice (n¼ 6) were treated,
that is, with anti-CD25 mAb, irrelevant IgG mAb or untreated 1 day prior to tumor inoculation and 4 days post tumor inoculation, 5 105
B16F10 cells were inoculated subcutaneously to the mice and tumour volume was monitored. (b) Tumor growth curves. Tumor growth from
anti-CD25 mAb, irrelevant IgG mAb and untreated is presented as tumor volume measurements from day 0 to day 12. Tumor volume was
calculated using the formula V¼ ab2/6. Data are presented as the means±standard error of the mean. *At days 6, 8, 10 and 12, compared anti-
CD25 mAb with untreated and IgG mAb, Po0.05. (c) Survival of tumor-bearing mice. Survival is presented using Kaplan–Meier survival curves.
*Compared anti-CD25 mAb with untreated B16F10 and IgG mAb, Po0.02.
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RESULTS
Suppression of primary tumor growth following administration of
anti-CD25 mAb
Mice were injected intraperitonealy with anti-CD25 mAb (PC61) or
rat IgG1 1 day prior to subcutaneous injection of B16F10 cells and
every 4 days post tumor inoculation (Figure 1a).20 Subsequent
monitoring of growth demonstrated that tumors grew signi-
ﬁcantly more slowly (Po0.05) in the presence of anti-CD25 mAb
when compared to untreated mice that had received no anti-
body or isotype control (immunoglobulin G, IgG; Figure 1b).
Irrelevant rat IgG mAb when administered at an equivalent dose
and time had no signiﬁcant effect on growth or survival when
compared with untreated tumors. Survival was improved sig-
niﬁcantly (Po0.02) when compared to the untreated group
and the irrelevant antibody-treated group from days 19 to 24
(Figure 1c).
Immunogene therapy suppresses the tumorigenicity of murine
melanoma B16F10 cells
B16F10 mouse melanoma is considered a poorly immunogenic
tumor (American Type Culture Collection). C57BL/6 mice
were challenged with 5 105 B16F10 cells subcutaneously and
subsequently electroporated with pGmCSF-b7.1, pMG or
untreated when tumors reached approximately 100mm3 in
volume. Notably, the immunogene group treated with pGmCSF-
b7.1 showed signiﬁcant reduction in tumor growth when
compared with the untreated group (Po0.05), data presented in
Figure 2a. This reduced tumor volume also correlated with
signiﬁcantly improved survival (Po0.02), however the immuno-
gene therapy was not curative (Figure 2b).
Combinational therapy of anti-CD25 and immunogene of B16F10
primary tumor
To determine how a combinational therapy approach might affect
tumor growth, we examined mice treated with a combination of
immunogene therapy and anti-CD25 mAb. Mice received either
anti-CD25 or rat IgG1, B16F10 cells and were then electroporated
with pGmCSF-b7.1, pMG or untreated when tumors reached
approximately 100mm3 in volume (Figure 3a). The pGmCSF-b7.1
and anti-CD25 mAb combination treatment regime signiﬁcantly
reduced the growth of the tumor when compared with the
untreated B16F10 tumor (Po0.05). There was no difference in
growth rate when pGmCSF-b7.1 and anti-CD25 combination
group was compared with pGmCSF-b7.1 and IgG group and
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Figure 2. Treatment of preestablished B16F10 using immunogene therapy. (a) Tumor growth of pGT141 GM-CSF-b7.1, pMG and untreated of
preestablished B16F10 tumor is presented from day 0 to day 12. Data are presented as the means±standard error of the mean. *At days 4, 6,
8, 10 and 12, compared pGmCSF-b7.1 with untreated B16F10 tumor, Po0.05. (b) Survival of immuogene-treated tumor-bearing mice. Survival
is presented using Kaplan–Meier survival curves. *Compared pGmCSF-b7.1 with untreated B16F10 tumor, Po0.02.
tumour
inoculation
Day
17
Timeline:
Ab
Day
10
Ab Ab
Day
5
Day
15
Ab AbGene
treatment
Day
12
0 5 10 15
0.0
0.5
1.0
1.5 Untreated B16F10
pMG + IgG
pGT141 GM-CSF/b71 +IgG
pMG + Anti-CD25
pGT141 GM-CSF/b71 +
AntiCD25
Days
0 10 20 30
*
0
20
40
60
80
100
Untreated B16F10
pMG + IgG
pGT141 GM-CSF/b71 +IgG
pMG + Anti-CD25
pGT141 GM-CSF/b71+
AntiCD25
Days
Pe
rc
en
t s
ur
vi
va
l
Tu
m
ou
r V
ol
um
e 
(cm
3 )
Day
-1
Day
0
Figure 3. Combination treatments with anti-CD25 and immunogene therapy. (a) Protocol of antibody administration, immunogene therapy
and tumor inoculation. C57/BJ6 mice (n¼ 6) were treated using the antibody regime previously described and combined with immunogene
when tumor reached approximately 100mm3 in volume, 5 105 B16F10 cells were inoculated subcutaneously to the mice and tumor was
monitored. (b) Tumor volume was measured and presented as means±standard error of the mean. *Combinational treatment (pGmCSF-b7.1
and anti-CD25 mAb) compared with untreated B16F10, Po0.005. (c) Survival is presented using Kaplan–Meier survival curves. *Compared
pGmCSF-b7.1/anti-CD25 mAb with untreated B16F10 tumor, Po0.02. mAb, monoclonal antibody.
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pMG and anti-CD25 group (Figure 3b). Importantly, those mice
receiving pGmCSF-b7.1 and anti-CD25 have signiﬁcantly improved
survival (Po0.05) compared to the untreated group (Figure 3c).
Overall, the combinational therapy approach had similar primary
tumor outcomes when compared to either modality alone. There
was no improvement in the combination over the single and
modality treatments.
Suppression of pulmonary metastasis from B16F10 tumor
We next sought to examine how effective the pGmCSF-b7.1 and
anti-CD25 combination would be against metastatic disease.
Twenty-four days post primary tumor induction (Figure 4a), lungs
were collected, weighed and photographed to determine the
number of metastatic nodules on the lung surface (Figure 4b). In
untreated mice with a primary B16F10 tumor, we observed
approximately 165 metastatic nodules on the lung surface
(Figure 4c). Mice in the single therapy groups (that is, pGmCSF-
b7.1 and IgG control or control pMG and anti-CD25) had signiﬁ-
cantly less metastatic nodules when compared with untreated or
pMG and IgG combination (Po0.05). Notably, only one mouse
(out of six) receiving the combination therapy (pGmCSF-b7.1 and
anti-CD25) displayed any metastatic lung nodules and thus this
group had signiﬁcantly reduced (Po0.05) lung metastases when
compared to single therapy or control groups.
T cell changes during treatment
In order to assess the effect the therapy had on T cells systemically
and locally in the B16F10 tumor model, we collected tumor and
spleens from anti-CD25 mAb, pGmCSF-b7.1 and the combination
of pGmCSF-b7.1 and anti-CD25 mAb treatment groups. As
expected, the anti-CD25 mAb-treatment group signiﬁcantly
depleted the CD4þCD25þFoxP3þ cell population in both the
tumor and spleen (Figures 5a and b). However, there was no
signiﬁcant change in the CD4þCD25þFoxP3þ tumor cell popu-
lation in the local pGmCSF-b7.1 treatment (Figure 5c). The
combination treatment with pGmCSF-b7.1 and anti-CD25 mAb
reduced both the CD4þCD25þFoxP3þ T-regs and the CD4þ
CD25þFoxP3þ T-cell population (activated CD4þ T cells;
Figure 5d).
DISCUSSION
Malignant melanoma is one of the most aggressive forms of
cancers and despite the development of molecular-targeted
therapies and improvements in surgery and radiotherapy many
patients succumb to recurrences and secondary’s resulting in poor
prognosis.8 The absence of an effective immune response to
metastatic melanoma is thought to contribute to this poor
prognosis.10 Several studies have described the presence and
accumulation of T-regs in tumors and their increase inﬁltrate to be
associated with this overall poor prognosis. This accumulation
increases with tumor volume and is coupled with the inhibition of
innate immune rejection of the tumor and precludes the
proliferation of effector cells.19–21 Building on these observations
we opted for a combinational regime of T-reg depletion and an
immunotherapy treatment.
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We choose an in-house plasmid encoding the cytokine GM-CSF
and the costimulatory molecule human B71, which we previously
demonstrated an effective recruitment of cytotoxic anti-tumor
response and the permanent elimination of a poorly immuno-
genic ﬁbrosarcoma tumor.15 B71 is usually expressed on the
membrane of antigen-presenting cells, whereas tumor cells
usually lack its expression and without this costimulatory signal,
T cells may become clonally anergic when the T-cell receptor
signal is delivered. B71-transduced tumor cells are expected
to present both the antigen (T-cell receptor) and the costimulatory
(CD28-mediated) signals to CD8þ cytotoxic T lymphocytes simul-
taneously, leading to efﬁcient activation of cytotoxic T lympho-
cytes without requiring the assistance of CD4þ helper T cells.19
The potential of immune-based cancer treatments has been
limited by negative immune-regulatory mechanisms, including
tumor-derived factors that support cellular immunity and also host
factors that suppress/inhibit cellular immune responses. Immune-
suppressive CD4þCD25þFoxP3þ T-reg accumulate in primary
and metastatic cancers and can prevent treatment-induced
immune responses, therefore T-reg depletion represents a
promising therapeutic approach. Consistent with other studies
we have shown that following anti-CD25 mAb administra-
tion, CD4þCD25þFoxP3þ T-regs were depleted signiﬁcantly
(Po0.001) with a minimal but signiﬁcant improved survival
probably due to the reduction in the metastatic load.
Previously we have demonstrated an improved local response
in a range of tumor types treated by electrogenetherapy with a
DNA plasmid encoding for the GM-CSF and the humanB7.1
(pGmCSF-b7.1).15,19 In keeping with this trend, the administration
of the pGmCSF-b7.1 was associated with extended survival in the
B16F10 primary tumor without being curative. This observation
could potentially be due to the level of T-regs accumulating in the
tumor subsequently blocking any additional immune recruitment,
even with an optimal expression of GmCSF-B7.1. It is well
documented that as a tumor grows the number of T-regs also
accumulates. Accumulations of T-regs impinge on the effective-
ness of any treatments and are associated with a negative clinical
outcome. Thus, suppression of T-regs so as to allow immune
recruitment to the site of the tumor post pGmCSF-B7.1 expression
would be a distinct advantage to any treatment approach.
We then decided to investigate the therapeutic potential of
local pGmCSF-b7.1 combined with systemic anti-CD25 mAb
against established subcutaneous tumor and lung metastasis
derived from the weakly immunogenic B16F10 melanoma model.
It was observed that there was a modest but signiﬁcant
improvement of primary tumor burden and survival observed
for each of the individual treatments given alone or for the
combinational-treated groups. However, the combinational ther-
apy was not effective in halting the primary tumor. The aim of all
anti-cancer therapies is long-lasting responses that also prevent
metastases and secondary tumors. The combination regime had a
remarkable therapeutic efﬁcacy of pre-existing lung metastases
when compared to the use of either treatment alone, indicating
that the suppression of T-regs with the anti-CD25 when combined
with the immunotherapy pGmCSF-B7.1 allowed for an enhanced
anti-tumor CD8 immune response with the decrease in the levels
of metastatic nodules.
In conclusion, we have demonstrated that T-reg depletion
strategy combined with an immunotherapy was effective in our
model. It was observed that the immunotherapy was only
effective once the T-regs were depleted. The combination of
immumotherapy and T-reg depletion resulted in an effective
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suppression of metastasis. We conclude that the combined
treatment was not effective in increasing the survival, but only
effective in suppression of metastases. Although we were unable
to stop the primary tumor, this treatment could ﬁt in as a
debulking therapy prior to surgery and has the potential to treat
the systemic and improving prognosis of metastatic melanoma
patients.
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